Postmarketing Surveillance for Angiotensin-Converting Enzyme Inhibitor Use During the First Trimester of pregnancy--United States, Canada, and Israel, 1987-1995

MMWR Morb Mortal Wkly Rep. 1997 Mar 21;46(11):240-2.

Abstract

Angiotensin-converting enzyme inhibitors (ACEIs) are effective antihypertensive drugs, but use of ACEIs during the second and third trimesters of pregnancy has been associated with a pattern of defects known as ACEI fetopathy. The predominant feature of the fetopathy is renal tubular dysplasia. Other associated conditions include hypocalvaria, intrauterine growth retardation (IUGR), and patent ductus arteriosus (PDA). These features may be related to fetal hypotension secondary to ACEI-induced decreases in fetal angiotensin or increased bradykinin. Although no adverse fetal effects have been linked to first trimester use of ACEIs, there has been no systematic evaluation of births to women with such exposures. To determine whether features of ACEI fetopathy occurred after first trimester exposure, in 1992 the Organization of Teratology Information Services (OTIS) in North America initiated the ACEI Registry; two members of the European Network of Teratology Information Services agreed to participate. This report presents findings from the ACEI Registry, which indicate that the infants of 66 women who self-reported first trimester only exposure to ACEI showed no evidence of renal tubular dysplasia.

MeSH terms

  • Adverse Drug Reaction Reporting Systems*
  • Angiotensin-Converting Enzyme Inhibitors / adverse effects*
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Antihypertensive Agents / adverse effects*
  • Antihypertensive Agents / therapeutic use
  • Canada / epidemiology
  • Ductus Arteriosus, Patent / chemically induced
  • Female
  • Fetal Diseases / chemically induced*
  • Fetal Growth Retardation / chemically induced
  • Humans
  • Hypertension / drug therapy*
  • Israel / epidemiology
  • Kidney Diseases / chemically induced
  • Pregnancy
  • Pregnancy Complications, Cardiovascular / drug therapy*
  • Pregnancy Outcome
  • Pregnancy Trimester, First
  • Registries
  • United States / epidemiology

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents